SR57227A is a selective 5-HT3 receptor agonist with oral activity and the ability to cross the blood-brain barrier; it exhibits antidepressant effects. It dose-dependently reduces immobility time in the forced swimming test in rats (ED50 = 7.6–14.2 mg/kg, i.p.) and shows efficacy after oral administration in both rats and mice, with effects lasting up to 6 hours in mice (20 mg/kg, p.o.). SR57227A also reduces escape failures by 50–60% in the learned helplessness model in rats (1–3 mg/kg, i.p.) and decreases isolation-induced aggressivity in mice by 50–85%, an effect antagonized by zacopride (1 mg/kg, i.p.).